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Interleukin-16 is a soluble ligand to the CD4 molecule
with chemotactic properties for CD4F cells and a
competence growth factor for CD4F T cells,
upregulating HLA-DR and the interleukin-2 receptor
CD25. There is also evidence for a synergistic effect
of interleukin-16 and interleukin-2 on the activation
of CD4F T cells. The infiltrate in mycosis fungoides,
the most common cutaneous T cell lymphoma, is
typically CD4F. We tested the possibility that inter-
leukin-16 is involved in the formation and progression
of these lesions. By reverse transcription–polymerase
chain reaction, interleukin-16 mRNA was detected in
18 of 18 mycosis fungoides lesions investigated. By
competitive reverse transcription–polymerase chain
reaction, interleukin-16 mRNA expression increased
with disease stage. Secreted interleukin-16 was
detected by enzyme-linked immunosorbent assay in
both Th1- and Th2-like T cell clones (as characterized
by their production of interferon-g and interleukin-
4) grown from lesional dermis and epidermis. By
IL-16 (interleukin-16), formerly known as lymphocytechemoattractant factor, is a soluble ligand to the CD41molecule and chemotactic to CD4-bearing cells such asCD41 T cells, eosinophils, and monocytes. Its function isstrictly dependent on the expression of CD4 on the target
cell. So far, it has been shown that IL-16 is produced by CD81
and CD41 T cells, eosinophils, and mast cells. It is believed that
IL-16 is transcribed into an mRNA of 2600 bp and translated into
a precursor protein. From the C-terminus of this precursor, a
14 kDa fragment is cleaved by caspase 3 and thought to be active
as a homotetramer of 56 kDa (Baier et al, 1997; Zhang et al, 1998).
IL-16 is considered as a competence growth factor for CD41
lymphocytes, as it induces expression of the IL-2 receptor (CD25)
and renders the cell responsive to exogenous IL-2 (Cruikshank
et al, 1987, 1994; Parada et al, 1998) without directly inducing
proliferation. Furthermore, there is evidence that IL-16 inhibits
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immunohistochemistry and in situ hybridization,
infiltrating lymphocytes were the main producers of
interleukin-16 whereas keratinocytes and endothelial
cells remained negative. Atypical cells with convo-
luted nuclei were also positive. In advanced mycosis
fungoides stages, many blast-like cells were positive,
but some larger blasts remained negative. Interleukin-
16 expression correlated positively with the expression
of interleukin-2 and its receptor CD25 in individual
skin lesions. Interleukin-2 expression, however, was
weak or absent in samples from uninvolved skin,
healthy controls and lesional psoriasis. Given the bio-
logic properties of interleukin-16 and the parallel
activation of the interleukin-2/CD25 pathway,
interleukin-16 might be involved in the recruitment
and stimulation of CD4F lymphocytes in mycosis
fungoides lesions and therefore contribute to the
perpetuation of the associated cutaneous inflamma-
tion. Key words: chemotaxis/cytokines/quantitative
competitive reverse transcription–polymerase chain reaction.
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antigen-specific immune responses (Cruikshank et al, 1996;
Theodore et al, 1996). As IL-16 and IL-2 have been shown to
activate CD41 T cells synergistically (Parada et al, 1998), IL-16
might be considered to activate CD41 T cells in an antigen-
independent manner.
Knowledge about the biologic functions of IL-16 is only
beginning to emerge. IL-16 has been shown to be expressed in
microglial cells in multiple sclerosis lesions (Schluesener et al, 1996)
and precedes the influx of lymphocytes into the airways after
bronchial challenge of asthmatics with allergen (Cruikshank et al,
1995). Until now, the expression of IL-16 in the skin has not been
investigated. The lesions of mycosis fungoides (MF), the most
common cutaneous T cell lymphoma (CTCL), are characterized
by local accumulation and activation of CD41 cells. IL-16 is
chemotactic for CD41 cells and regulates the responsiveness to
IL-2, which is thought to be expressed in MF lesions (Saed et al,
1994; Vowels et al, 1994). In this study we present evidence that
the IL-16/CD4 and IL-2/CD25 pathways might constitute a
positive regulatory system in the formation and progression of
MF lesions.
MATERIALS AND METHODS
Skin samples Skin punch biopsies (6 mm) were obtained from lesional
(patch n 5 8, plaque n 5 7, and tumor stage n 5 3) and uninvolved skin
(n 5 3, at least 10 cm distant to the lesion) of patients with MF and split
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in half for cryopreservation and paraffin embedding. Additional punch
biopsies were taken for the generation of T cell clones. As controls, biopsies
were also taken from normal skin of healthy volunteers (n 5 9) and from
the active border of chronic psoriasis plaques (age of the plaques . 2 mo;
n 5 9). Psoriasis patients were discontinued from any systemic treatment
including psoralen ultraviolet A at least 4 wk and topical treatment other
than emollients at least 2 wk before skin sampling. Informed consent was
obtained in all cases.
Generation of T cell clones and characterization by enzyme-linked
immunosorbent assay (ELISA) T cell clones were grown from lesional
dermis and epidermis as described before (Lefkovits and Waldmann, 1984;
Ramb-Lindhauer et al, 1991). Briefly, dermis and epidermis were separated
by overnight incubation (4°C) with dispase and single cell suspensions
were prepared. The dermal solution was nylon-gaze filtered (50 µm).
T cells comprised between 0.6% and 56% in the epidermal and a mean of
23% in the dermal preparations (viability . 90% by Trypan Blue exclusion).
Various dilutions were cocultured with 2 3 104 irradiated autologous
feeder cells in limiting dilution plates [Iscove’s medium containing 10%
fetal bovine serum, 1% penicillin/streptomycin (Biochrom, Berlin,
Germany), 20 U IL-2 per ml, 5 ng IL-4 per ml, 1 ng IL-7 per ml (all
cytokines PBH, Hannover, Germany), and 10 µg phytohemagglutinin per
ml (Sigma, Deisenhofen, Germany)]. After 14 d of culture, only those
cultures with a high probability of clonal growth (dilutions with less than
37% of cultures growing) (Lefkovits and Waldmann, 1984) were further
expanded. Twenty-four hours before ELISA (Biosource, Ratingen,
Germany), cytokine-containing medium was replaced by medium supple-
mented with 10% fetal bovine serum and 10 µg Concanavalin A per ml
only. IL-4, interferon-γ, and IL-16 were determined by ELISA. Clones
were phenotyped (four CD41, three CD81, one not determined) and
characterized as Th1-like when they predominantly produced interferon-γ
(range: 1.8–5 ng per ml) over IL-4 (range: 0–0.5 ng per ml), and as Th2-
like when they predominantly produced IL-4 (range: 0.1–0.5 ng per ml)
over interferon-γ (no interferon-γ detected). Values were determined
in duplicate.
RNA extraction and cDNA synthesis In a subgroup of patients
(n 5 3) dermis and epidermis were investigated separately using a modified
split-skin technique (Saed et al, 1994). Briefly, samples (freshly taken or
previously stored at –70°C) were placed in 0.15 M NaCl at 60°C for
5 min and then transferred to ice-cold 0.15 M NaCl. After another 5 min,
dermis and epidermis were separated by sterile forceps. Thirty consecutive
20 µm sections were used for RNA extraction from whole skin samples.
RNA was extracted from the slices according to the instructions of the
manufacturer (RNeasy, Qiagen, Hilden, Germany) and eluted in 30 µl
RNAse-free water (0.1% diethylpyrocarbonate, Sigma). RNA from T cell
clones (1 3 106 cells) was extracted using Trizol (GIBCO, Eggenstein,
Germany) and obtained in 30 µl RNAse-free water. RNA content was
determined spectrophotometrically. One microgram of RNA was used for
reverse transcription after a DNAse (FPLC-pure DNAse I, Pharmacia,
Freiburg, Germany) digestion step. Synthesis was performed in a total
volume of 50 µl RNAse-free water including 1.5 µM pd(T)12–18
(Pharmacia), 0.4 mM of each deoxynucleotidetriphosphate (dNTP, MBI
Fermentas, St Leon-Rot, Germany), and 200 U of reverse transcriptase
(Superscript II, GIBCO).
Reverse transcriptase–polymerase chain reaction (RT–PCR) After
cDNA synthesis, cDNA was immediately tested for successful synthesis by
PCR (Taq DNA polymerase, GIBCO) for β-actin (β-actin F 59→39:
CCCAGCCATGTACGTTGCTAT, β-actin R 59→39: GGGTGGCTT-
TTAGGATGGCAA, product size: 1047 bp, cycle conditions: 2 min 95°C,
followed by 35 cycles of 45 s 95°C, 45 s 60°C, 90 s 72°C, followed by a
final elongation step of 10 min at 72°C, all oligonucleotide primers by
GIBCO). Oligonucleotide primer sequences were designed according to
the following sequences published in GenBank as characterized by their
accession numbers: β-actin (X00351), IL-2 (X01586), IL-16 (M90391).
PCR products were visualized on 1% or 2% agarose gels by staining with
ethidium bromide. A PCR reaction was considered positive when the
band was detected by the gel analysis software (Herolab, Wiesloch,
Germany), negative controls with water instead of cDNA were always
included. PCR conditions were: IL-2 F: TAATCACTACTCACAGTAA,
IL-2 R: CCAATCTACATAGATACTATA, 744 bp, 3 min 95°C, 38
cycles of 1 min 95°C, 1 min 44°C, 2 min 72°C, and a final elongation
step as before, IL-16 F2: CACGGAAGCCAAGGAAGACG, IL-16 R2:
GGGGCGGCAGCAGAGAC, 903 bp, 2 min 95°C, 35 cycles of 45 s
95°C, 45 s 58°C, 90 s 72°C, and a final elongation step as before). All
PCR products used in this study were identified by cycle sequencing.
Cloning of PCR products and quantitative competitive RT–
PCR Internal standards were generated as previously described (Blaschke
et al, 1996). Briefly, the β-actin F/R and IL-16 F/R (IL-16 F: CGAAGAC-
TCAGCTGCAAAT, IL-16 R: GCCAGGCATGAATGTCATA,
1223 bp, 2 min 95°C, 35 cycles of 45 s 95°C, 45 s 50°C, 90 s 72°C, and
a final elongation step as before) PCR products were cloned into the SmaI
restriction site of the transcription vector pBluescript (pBS, Stratagene,
Heidelberg, Germany). A 224 bp fragment was removed from the β-actin
construct by restriction enzyme digestion with SauI (position 815) and
PpuMI (position 591), and a 285 bp fragment was removed from the IL-
16 construct by digestion with BalI and CelII (positions 1488 and 1203,
respectively). The shortened constructs, termed internal standards, were
linearized, quantitated, and dilution series were prepared. For quantitative
competitive PCR, 2-fold dilution series of cDNA were prepared in water.
PCR reactions containing a known constant amount of the internal
standard were prepared, and cDNA dilution aliquots were added. After
PCR, agarose gel electrophoresis was performed and the upper (representing
wild-type cDNA to be quantitated) and lower (β-actin: 823 bp by PCR,
IL-16 F2/R2: 628 bp, representing a known amount of internal standard)
bands were quantitated by densitometry. After correcting for PCR product
size, ratios of the corresponding upper and lower bands from the PCR
reaction were used to quantitate the molar amounts of β-actin or IL-16
cDNA molecules in the cDNA sample. Values were determined in
duplicate. For each sample, the ratio of the molar amounts of IL-16 and
β-actin per µl cDNA was calculated.
Immunohistochemistry Detection of IL-16 required pretreatment of
paraffin sections by microwave. Sections were placed in fresh citrate buffer
and left to cool for 30 min. Incubation with normal rabbit serum (DAKO,
Hamburg, Germany; 1:5) for 30 min at room temperature was followed
by incubation at 4°C overnight with mouse anti-IL-16 IgG1 (hybridoma
supernatant, a kind gift of W. Schlu¨sener, Tu¨bingen, Germany) in a moist
chamber. For the detection of IL-16 positive cells, slides were then
incubated (30 min) with biotinylated rabbit anti-mouse IgG polyclonal
antibody (DAKO), followed by incubation with streptABComplex/HRP
(DAKO) for 10 min at room temperature. Peroxidase activity was visualized
by using 3-amino-9-ethylcarbazole as the chromogen. Slides were coun-
terstained with hematoxylin. In addition, on serial paraffin sections CD4
(Novocastra, Newcastle, U.K.) was detected using the same method
according to the recommendations of the manufacturer. The same ABC
technique was used to identify CD25- (Novocastra), CD4-, and CD8-
positive cells on acetone-fixed cryostat-cut 4 µm sections. Isotype controls
were always included. Monoclonal antibodies were obtained from DAKO
unless indicated otherwise.
In situ hybridization The IL-16 a/b RT–PCR product (IL-16 a:
ATGCCCGACCTCAACTCCTCCACT, IL-16 b: GCCACCCAGCT-
GCAAGATTTC, 261 bp, 2 min 95°C, 35 cycles of 45 s 95°C, 45 s 62°C,
90 s 72°C, and a final elongation step as before) was cloned into pBS as
described before. Using this construct as a template, a PCR was carried
out using oligonucleotide primers specific for the T3- and T7-promotor
regions of the plasmid. Digoxigenin-11-UTP-labeled (DIG RNA labeling
mix, Boehringer) sense and anti-sense probes were generated by in vitro
transcription with T3- or T7-polymerase (Promega, Mannheim, Germany)
using 200 ng of the PCR product as template. The amount of transcript
was monitored by agarose gel electrophoresis and labeling efficiency was
controlled by dot blot analysis of serial probe dilutions. In situ hybridization
was performed according to Breitschopf et al (1992). Briefly, tissue sections
were deparaffinized and rehydrated in serial dilutions of ethanol. Samples
were permeabilized by Proteinase K (Sigma, 10 µg per ml, 20 min, 37°C).
For blocking endogenous alkaline phosphatase, slides were incubated with
0.25% acetic anhydride (10 min at room temperature) and dehydrated in
serial dilutions of ethanol. Probes (1:50–1:100 according to dot blot analysis)
were then added, slides were covered and denatured (5 min, 85°C).
Hybridization was performed overnight at 62°C in a sealed humidified
chamber containing 50% formamide. Afterwards, unbound probe was
removed by RNAse digestion (Boehringer Mannheim, Mannheim, Ger-
many, 20 µg per ml, 30 min, 37°C) and by the following posthybridization
washes: 1 3 sodium citrate/chloride buffer/0.1% sodium dodecyl sulfate
at room temperature (2 3 5 min) and 0.2 3 sodium citrate/chloride
buffer/0.1% sodium dodecyl sulfate at hybridization temperature
(2 3 10 min). Finally, the sections were washed in Tris-buffered saline
(pH 7.4) containing 0.1% Tween-20 (Boehringer). Specifically bound
probe was detected by a polyclonal sheep anti-digoxigenin antibody F(ab)2-
fragment (1:500, Boehringer) conjugated with alkaline phosphatase and
the substrates NBT/X-phosphate (Boehringer) for color reaction. Speci-
mens were counterstained with hemalaun. The sense probe was always
included as the negative control.
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Table I. Coexpression of IL-2 and IL-16 in MF lesionsa
IL-2 IL-16
Tissue source n/total (%) n/total (%)
Normal skin 1/9 (11%) 5/9 (56%)
Uninvolved MF 0/3 (0%) 3/3 (100%)
Active psoriasis 2/9 (22%) n.d.b
Patch stage MF 6/8 (75%) 8/8 (100%)
Plaque stage MF 6/7 (86%) 7/7 (100%)
Tumor stage MF 3/3 (100%) 3/3 (100%)
aPunch biopsy skin samples were investigated for IL-2 and IL-16 mRNA expression
by RT–PCR.
bNot determined.
RESULTS
IL-16 and IL-2 are coexpressed in MF lesions In normal skin
from healthy volunteers as well as in uninvolved and lesional skin
of MF patients, IL-16 could be detected by RT–PCR (Table I).
IL-16 was more frequently expressed in uninvolved (three of three)
than in normal (five of nine) skin samples. Furthermore, IL-16
mRNA expression was confirmed in all 18 lesional samples. In
contrast to IL-16, IL-2 mRNA expression was rare in normal (one
of nine) skin and in uninvolved (none of three) skin from CTCL
patients. In addition to MF, IL-2 mRNA expression was also
investigated in psoriatic skin where it could only be detected in
two of nine lesions. Coexpression of IL-2 and IL-16 mRNA,
however, was a striking feature already in early stage MF (Table I).
IL-16 mRNA expression increases with disease progres-
sion To analyze whether the amount of IL-16 mRNA expressed
in the dermis and epidermis of lesional skin was stage dependent,
total skin biopsies from uninvolved skin (n 5 2), plaque stage (n 5
3), and tumor stage lesions (n 5 3) were investigated by quantitative
competitive RT–PCR. To characterize further the source of IL-
16 production, samples from an individual patient were obtained
from uninvolved skin, a plaque and a tumor stage lesion at the
same time point, and dermis and epidermis were investigated
separately. Epidermis of uninvolved skin could not be analyzed as
cDNA synthesis was not successful. Comparing IL-16 mRNA
expression between the different stage lesions, there seemed to be
a stage-dependent increase in IL-16 mRNA expression (Fig 1). In
general, comparing different compartments of the same disease
stage, higher levels of IL-16 were detected in dermis than in
epidermis.
IL-16 is produced by Th1- and Th2-like lesional dermal and
epidermal CD41 and CD81 T cell clones The proinflam-
matory functions of IL-16 share certain similarities with Th1-type
cytokines. So far, a possible restriction of IL-16 production to
either Th1- or Th2-like T cells has not been investigated on a
clonal level. To address this issue further, selected T cell clones of
lesional dermis and epidermis were characterized as belonging to
either Th1- or Th2-phenotype by their cytokine profile. Cells
shown preferentially to produce interferon-γ over IL-4 (as detected
by ELISA) were characterized as Th1-like and vice-versa. By this
characterization, four clones showed a Th1-like cytokine profile,
and the remaining four clones showed a Th2-like profile. Regardless
of their CD4/CD8 and Th1/Th2 phenotype, all clones were
positive for IL-16 by RT–PCR (data not shown) and secreted
similar amounts of IL-16 protein into the supernatant as detected
by ELISA (Fig 2), indicating that the production of IL-16 is not
restricted to either cell phenotype. Of the eight clones investigated,
six were of dermal and two of epidermal origin. This argues against
a selective production of IL-16 by the epidermotropic T cells as a
possible explanation for the epidermotropism found in MF.
The vast majority of infiltrating lymphocytes in MF lesions
are CD41, IL-16 producing T cells which express IL-2 and
its receptor CD25 Plaque and tumor stage lesions were used to
Figure 1. Stage-dependent increase in IL-16 expression. (A) IL-16
mRNA expression was investigated in different stage MF lesions
(uninvolved skin n 5 2, plaque stage n 5 3, tumor stage n 5 3, circles,
mean 6 SD) by quantitative competitive RT–PCR. In an individual
patient, skin samples were separated into dermis (black bars) and epidermis
(white bars) and values determined in triplicate (mean 6 SD). IL-16
levels were standardized for β-actin (expressed as IL-16/β-actin ratio).
*Uninvolved epidermis was not investigated. (B) On a representative gel
a constant amount of the internal standard for IL-16 (628 bp, lower panel)
competes against wild-type IL-16 (903 bp, upper panel) contained in 2-fold
dilution series of sample cDNA (amounts indicated in microliters). Given
the amount of internal standard and sample cDNA used in this titration
and PCR band intensities, the amount of IL-16 cDNA present in 1 µl of
sample cDNA can be calculated. By standardizing IL-16 for β-actin, IL-
16 expression can be compared between different samples.
Figure 2. IL-16 is produced in Th1- and Th2-like lesional T cell
clones. T cell clones were generated from the dermis (D1, 2, 6, 11, 16,
18, black bars) and epidermis (E14, 20, white bars) of a patient with plaque
stage CTCL. Clones were characterized as Th1- or Th2-like according to
their cytokine profile. Levels of secreted IL-16 were determined in duplicate
(mean 6 SD).
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Figure 3. IL-16 and its receptor CD4
as well as IL-2 and its receptor CD25
are expressed in MF lesions. A punch
biopsy from a patient presenting with
plaque stage lesions and another patient
with tumor lesions was split in half for
cryopreservation and paraffin embedding.
RT–PCR and serial-section immunohisto-
chemistry were performed. (A) Representat-
ive RT–PCR results for IL-2 (lanes 2–5) and
IL-16 (lanes 6–9) from both lesions (plaque:
lanes 3 and 7, tumor: lanes 4 and 8) and from
normal skin (lanes 2 and 6). For the negative
control, cDNA was replaced by water (lanes
5 and 9). Lane 1: molecular weight markers
(MWM). Immunohistochemical staining was
performed on serial sections for CD4 (B)/
IL-16 (C) (tumor stage) and for CD4 (D)/
CD25 (E) (plaque stage). Scale bars: 100 µM.
IL-16 is strongly expressed on the infiltrating
lymphocytes, which are mainly CD41. Only
a few CD81 lymphocytes are present (data
not shown). A considerable portion of the
lymphocytes stain strongly positive for
CD25.
Figure 4. Infiltrating lymphocytes are
the main producers of IL-16 in normal
skin and MF lesions. Sections from normal
skin, plaque and tumor stage MF were stained
for IL-16. In serial sections from normal
skin, a few perivascular cells including
lymphocytes stain positive for IL-16 in by
immunohistochemistry (A) and in situ
hybridization (B), scale bar: 100 µm. In plaque
stage lesions, most infiltrating cells are posit-
ive, including atypical lymphocytes with
convoluted nuclei (C, D), scale bar: 87.5 µm.
In tumor stage lesions, a sheet-like infiltrate
of blast can be observed. Most cells are
positive for IL-16 (E, F), but on a weaker
level than the smaller lymphocytes. Within
this infiltrate, a few larger blasts may remain
negative (E, see arrows), scale bar: 56 µm.
Isotype (G) and sense probe (H) controls
were always included.
demonstrate the expression of IL-16 and its receptor CD4 as well
as the receptor–ligand pair IL-2/CD25 (Fig 3). In addition, IL-16
expression was demonstrated in normal skin, a plaque and a tumor
stage lesion, and correlated to in situ hybridization (Fig 4). By RT–
PCR, IL-16 could be detected in all samples, whereas IL-2 could
not be detected in normal skin (Fig 3A). Immunohistochemistry
and in situ hybridization confirmed that the infiltrating lymphocytes
were the main producers of IL-16. The vast majority of the
infiltrating cells were CD41 (Fig 3B) with only a few CD81 cells
(data not shown). On serial sections, most of the CD41 cells also
stained positive for IL-16 (Fig 3C). In line with the simultaneous
detection of IL-16 and IL-2 in these lesions, a considerable portion
of the CD41 lymphocytic infiltrate (Fig 3D) stained strongly
positive for CD25 (Fig 3E) on serial sections.
In normal skin, IL-16 mRNA expression could be attributed to
the sparse perivascular lymphocytic infiltrate by in situ hybridization
(Fig 4B). This pattern of IL-16 production was confirmed on
protein level by immunohistochemistry (Fig 4A). In all normal
and lesional samples investigated, keratinocytes and endothelial cells
were negative. In plaque stage, most of the infiltrating lymphocytes
were positive for IL-16 by immunohistochemistry (Fig 4C) and in
situ hybridization (Fig 4D). In advanced tumor stage, a homogen-
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eous infiltrate of blastoid cells positive for IL-16 dominated (Fig 4E),
although these cells stained less intensely than the smaller lympho-
cytes. Moreover, indicating tumor cell heterogeneity, large blastoid
cells were observed, which did not stain for IL-16. This was
confirmed by in situ hybridization (Fig 4F).
DISCUSSION
CTCL are characterized by the proliferation of a malignant T cell
clone dominating in the skin, the most common form is MF.
Whereas the disease is initially confined to the skin with eczematous
patches which progress to plaque-like lesions and tumors, at later
stages systemic involvement occurs and the disease then often
follows a rapid, fatal course.
The lesions of MF are characterized by an accumulation of
mainly CD41 lymphocytes. At early disease stage, the infiltrate is
believed to contain only a small amount of malignant T cells of
clonal origin, whereas the majority of cells belong to the benign
inflammatory infiltrate. Both recirculating lymphocytes and locally
proliferating cells are thought to contribute to the formation of
MF lesions. It is yet unknown why the disease remains skin-bound
for a considerable time course and which local factors contribute
to the formation of skin lesions.
IL-16, which is produced by CD41 and CD81 lymphocytes,
but also eosinophils and mast cells, acts specifically on CD41 cells
through the CD4 molecule as its receptor. IL-16 is a chemoattractant
for CD41 cells. It has also been shown to activate CD41 T cells
and to upregulate the IL-2 receptor IL-2Rα (CD25) (Cruikshank
et al, 1987, 1994), thereby rendering the cells responsive to IL-2.
Furthermore, a synergistic effect of IL-16 and IL-2 on the activation
of CD41 T cells (Parada et al, 1998) has recently been demonstrated.
In view of the well-known accumulation of CD41 lymphocytes
in MF lesions and the biologic functions of IL-16 on these cells,
we addressed the question whether IL-16 might be involved in
the formation and perpetuation of this disease. To investigate
whether coactivation of lymphocytes could be an additional mech-
anism of driving MF lesions, we also analyzed IL-2 and CD25
expression in these lesions.
By RT–PCR, conflicting results about the presence of cytokines
in skin lesions of MF have so far been obtained (Saed et al, 1994;
Vowels et al, 1994). This indicates that using RT–PCR alone might
not be sufficient to characterize the true cytokine milieu. Its results
are not quantitative (Gilliland et al, 1990) and due to the high
sensitivity might produce positive results of doubtful biologic
significance. In this study, a quantitative competitive RT–PCR
employing an internal standard was used (Siebert, 1992; Blaschke
et al, 1996), combining a quantitative method with the sensitivity
of the RT–PCR needed to detect mRNA from small amounts of
tissue. As RT–PCR only detects mRNA, however, we included
investigations of protein expression. Finally, the use of in situ
hybridization and immunohistochemistry allowed the detection of
IL-16 expression on a single cell level.
We could demonstrate that IL-16 is expressed in MF lesions
in high amounts. IL-16 mRNA was detectable in normal and
uninvolved skin, which predominantly seemed to be attributable
to perivascular lymphocytes. Using quantitative competitive RT–
PCR, there appeared to be a stage-dependent increase in IL-16
mRNA expression in the small number of samples studied, indicat-
ing increased levels of IL-16 in advanced lesions. This was confirmed
by in situ hybridization studies and immunohistochemistry. With
disease progression, there was an increasing number of lesional
lymphocytes expressing IL-16. If the malignant clone or inflam-
matory cells or both were sources of IL-16 was not studied. By
immunohistochemistry, the vast majority of the infiltrating cells
was CD41.
Considering its chemotactic properties for CD41 lymphocytes,
it might be hypothesized that the increased lesional production of
IL-16 accounts for the immigration of CD41 lymphocytes that
constitute the inflammatory, nonmalignant infiltrate. Furthermore,
IL-16 acts as a competence growth factor for CD41 T cells
by upregulating HLA-DR and CD25. We have confirmed the
expression of CD25 on a considerable number of lesional lympho-
cytes even in early MF lesions. In contrast, CD25 was rarely
expressed on the lymphocytic infiltrate in benign chronic inflam-
matory diseases like psoriasis or atopic dermatitis (data not shown).
This indicates that lymphocytes in MF lesions are specifically
activated and responsive to IL-2.
By RT–PCR, IL-2 was frequently detected even in early patch-
stage lesions, whereas expression of IL-2 was rare in active psoriasis,
which is believed to be dominated by a Th1-type infiltrate (Schlaak
et al, 1994). Our failure to detect IL-2 mRNA in active, untreated
psoriatic lesions could indicate a low sensitivity of the IL-2 RT–
PCR but is in line with a recent report by others.1 The frequent
and consistent finding of IL-2 in MF lesions, however, would at
least indicate the presence of considerably higher amounts of IL-2
mRNA than in psoriatic lesions. Thus, together with the IL-16-
induced expression of the IL-2 receptor CD25, IL-2 could induce
proliferation in IL-16-primed CD41 lymphocytes in MF. There-
fore, in addition to IL-16-induced chemotaxis, the accumulation
of CD41 lymphocytes in MF lesions might also result from the
local proliferation of benign bystanders and malignant lymphocytes
caused by the synergistic effects of IL-16 and IL-2. Synergistic
activation seems to be characteristic for MF as we were not able
to detect a similar coexpression in benign inflammatory lymphocytic
dermatoses.
In this study we have provided evidence for the presence of
IL-16 within MF lesions. The methods we have used here did not
allow to directly demonstrate biologic activity of IL-16. The
presence of IL-16 protein in the lesions, the accumulation of CD41
T cells, and the strong expression of CD25 on a considerable
portion of the infiltrating lymphocytes, however, would argue for
the presence of biologically active IL-16. As described earlier (Saed
et al, 1994; Vowels et al, 1994), we have demonstrated IL-2 mRNA
in MF lesions. This indicates that the IL-16-dependent induction
of the IL-2/CD25 pathway might be involved in the activation
and proliferation of CD41 lymphocytes in MF.
Taken together, the production of IL-16 by infiltrating T
lymphocytes in early lesions appears as a chemotactic signal for
circulating lymphocytes. In the context of IL-16-mediated activa-
tion of lymphocytes and induction of CD25, the local production
of IL-2 could provide a proliferative stimulus, further increasing
lymphocyte accumulation. Therefore, the simultaneous secretion
of chemotactic and activating factors might contribute to a favorable
cutaneous microenvironment promoting the continuous develop-
ment of MF lesions. IL-16 expression, however, is not restricted
to MF alone and additional factors must be operative in lymphoma
manifestation. Further studies are needed to define more precisely
the part of IL-16 in the pathogenesis of CTCL.
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Stefanie Heege, Ms Desiree Wolters, and Mr Thomas Juergens.
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